Comparison of the effects of Bromocriptine and Cabergoline on the occurrence of pregnancy in infertile wome
Phase 3
- Conditions
- Hyperprolactinemic infertile women.Female infertility associated with anovulation
- Registration Number
- IRCT138806142420N1
- Lead Sponsor
- Research deputy of Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 188
Inclusion Criteria
1) Primary or secondary infertility, 2) Hyperprolactinemia with or without galactorrhea (prolactin>20ng/ml), 3) Normal HA except high prolactin level, normal HSG or laparoscopy and normal SA.
Exclusion criteria: 1) other causes of infertility such as tubal factor, male factor or unexplained infertility, 2) nausea, vomiting, orthostatic hypotension, chronic hypertension, headache, 3) sensitivity to ergot derivatives, 4) macroadenoma of pituitary gland, 5) previous use of bromocriptine or cabergoline
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The occurrence of pregnancy. Timepoint: At 6-7 weeks of gestational age. Method of measurement: Transvaginal sonography.
- Secondary Outcome Measures
Name Time Method Treatment side effects. Timepoint: Every 4 weeks. Method of measurement: Check list.;Serum prolactin level. Timepoint: 4 weeks after treatment. Method of measurement: Laboratory measurment.